Rapidly Evolving Extensive Fluorodeoxyglucose-Positive Soft-Tissue Activity During Nivolumab Therapy

JAMA Oncol. 2019 May 1;5(5):730-731. doi: 10.1001/jamaoncol.2018.6431.

Authors

Joanna Mangana¹, Caroline S Buset¹, Reinhard Dummer¹

Affiliation

¹ Department of Dermatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.

PMID: 30676614
DOI: 10.1001/jamaoncol.2018.6431

No abstract available

Publication types

Case Reports

MeSH terms

Adult
Antineoplastic Agents, Immunological / adverse effects*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Female
Fluorodeoxyglucose F18
Humans
Ipilimumab / therapeutic use
Melanoma / diagnostic imaging
Melanoma / drug therapy*
Nivolumab / adverse effects*
Panniculitis / chemically induced*
Panniculitis / diagnostic imaging
Positron Emission Tomography Computed Tomography
Skin Neoplasms / diagnostic imaging
Skin Neoplasms / drug therapy*

Substances

Antineoplastic Agents, Immunological
Ipilimumab
Fluorodeoxyglucose F18
Nivolumab